Expanding access to simpler, more optimal HIV treatment regimens for children and adults has been a top priority for UNITAID since its creation over ten years ago.  UNITAID and WHO are working closely with key partners across the global health landscape to advance the optimisation of antiretroviral treatment (ARV) for low- and middle-income countries.

Thursday 21 July, 18:30-20:30, Session Room 5. 

Satellite Session

The Drugs for Neglected Diseases initiative (DNDi), the Clinton Health Access Initiative (CHAI), UNITAID, and the National Empowerment Network of People living with HIV/AIDS in Kenya (NEPHAK) will be sharing practical and programmatic experience – including both successes and challenges – developing and introducing new paediatric ARV formulations.

This Satellite Session will explore how to ensure that when optimal formulations are developed, they are rapidly adopted and introduced so that large-scale treatment of infants and young children with HIV can be implemented and sustained. The Satellite will bring in perspectives from WHO and affected communities as well as from country implementers, product developers, donor agencies, and non-governmental organizations.

For more information download the event flyer [PDF, 4 MB]

Wednesday 20 July, 18:30-20:30. Session Room 4.

SATELLITE SESSION

CHAIRS:
Owen Mugurungi, Ministry of Health-Zimbabwe

Rachel Baggaley, World Health Organization

PANEL MODERATOR:
Rosanna Peeling

Increased uptake of HIV testing is crucial to reaching the United Nation's (UN) 90-90-90 goal. HIV self-testing (HIVST) could play an important role in increasing uptake and frequency of testing, while ensuring linkage into care.

UNITAID strives to find new ways to prevent, diagnose and treat HIV more quickly and effectively. UNITAID’s involvement at the International AIDS Conference in 2016 in Durban, South Africa will showcase its work to promote innovations in testing, treatment and monitoring of HIV with a range of partners including UNICEF, Population Services International, USAID, The Global Fund, Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and the Drugs for Neglected Diseases initiative.